Dan Veljovich, MD
Dr. Dan Veljovich is a gynecologic oncologist at Swedish Cancer Institute and Swedish Medical Center in Seattle, Washington, and trains fellows and residents as a Clinical Associate Professor at the University of Washington School of Medicine, and for the Swedish Medical Center OB/GYN Residency.
He earned his medical degree and completed his residency in Obstetrics and Gynecology at the University of Virginia School of Medicine and completed his fellowship at the University of North Carolina.
His clinical interests include surgical and medical treatment of gynecologic cancers, especially ovarian cancer, and he is involved in multiple clinical trials evaluating novel therapies in ovarian cancer, and he was involved in clinical trials of parp inhibitors and angiogenesis inhibitors prior to FDA approval of these drugs.
He co-initiated the first robotic surgery program for gynecologic cancers in the Pacific Northwest in 2006 and has performed over 2500 such procedures since that time.
A fellow of the American Congress of Obstetricians and Gynecologists and the American Society of Clinical Oncologists, he is a past President of the Seattle Gynecologic Society and has served on the Program Committee of the Society of Gynecologic Oncologists in 2010 and 2020. He has consistently been named a “Top Doctor” in gynecologic oncology in Seattle Magazine and Seattle Metropolitan Magazine.
In his free time he enjoys endurance running, snowboarding, hiking, spending time with his family, and walking his dog.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GSKTopic:Parp inhibitor consulting and speaker's bureauDate added:08/24/2022Date updated:04/25/2024Relationship end date:08/24/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AstraZenecaTopic:Parp inhibitor consulting and speaker's bureauDate added:08/24/2022Date updated:04/25/2024Relationship end date:08/24/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:EisaiTopic:Immunotherapy and TKI for uterine cancerDate added:08/24/2022Date updated:04/25/2024Relationship end date:08/24/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MerckTopic:Immunotherapy and TKI for uterine cancerDate added:08/24/2022Date updated:04/25/2024Relationship end date:08/24/2022